Latent tuberculosis infection in a drug treatment centre

S. Neves, R. Duarte, M. Mota, A. Caiado, J. Amado, I. Pascoal, M. Vanzeller, S. Conde, J. Sapage, M. J. Forte (Vila Nova de Gaia, Portugal)

Source: Annual Congress 2002 - Clinical events related to tuberculosis
Session: Clinical events related to tuberculosis
Session type: Thematic Poster Session
Number: 2266
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Neves, R. Duarte, M. Mota, A. Caiado, J. Amado, I. Pascoal, M. Vanzeller, S. Conde, J. Sapage, M. J. Forte (Vila Nova de Gaia, Portugal). Latent tuberculosis infection in a drug treatment centre. Eur Respir J 2002; 20: Suppl. 38, 2266

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment of latent infection with Mycobacterium tuberculosis: update 2010
Source: Eur Respir J 2011; 37: 690-711
Year: 2011



Diagnosis and treatment of latent tuberculosis infection
Source: Eur Respir Monogr 2018; 82: 381-398
Year: 2018


Completion of treatment for latent tuberculosis infection
Source: Annual Congress 2011 - Clinical tuberculosis
Year: 2011

Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018

How should we treat latent tuberculosis infection?
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003

Treatment failure in tuberculosis
Source: Eur Respir J 2007; 29: 561-564
Year: 2007



Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1594-1595
Year: 2016


Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1592-1594
Year: 2016


Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2015; 46: 1397-1406
Year: 2015



Latent tuberculosis infection: a new paradigm
Source: International Congress 2019 – State of the art session: Respiratory infections
Year: 2019


Diagnosis of latent tuberculosis infection
Source: ERS Live 2007
Year: 2007

Latent tuberculosis infection as a cause of tuberculosis disease
Source: Eur Respir J 2003; 22: Suppl. 45, 157s
Year: 2003

Latent tuberculosis infection in children in contact with pulmonary tuberculosis patients
Source: Annual Congress 2010 - Tuberculosis in children
Year: 2010


Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005

What is latent tuberculosis infection (LTBI)?
Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections
Year: 2009


Cost-effectiveness of two latent tuberculosis infection screening strategies
Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity
Year: 2018




Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis
Source: Eur Respir J 2007; 30: 321-332
Year: 2007



The dynamics of tuberculosis incidence and diagnostics of latent tuberculosis tuberculosis infection in children of Ukraine.
Source: International Congress 2018 – Groups who are susceptible to tuberculosis: children, pregnant women and elderly people
Year: 2018

Can we define latent tuberculosis infection?
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003